Professor Arne Astrup
MD, DMSc (DK)
World-leading researcher in nutrition and obesity and co-discoverer of GLP-1’s role as a satiety hormone.
“I am excited to be part of Azento Health, as their approach for supporting GLP-1 patients is unique.”
We founded Azento Health on a simple belief: the breakthrough in obesity treatment should be matched by a breakthrough in how we support people throughout their weight-loss journey.
OUR AMBITION
Better Weight Loss.
Our purpose
To enhance overall health and contribute to better obesity care through optimised gut health, microbiome science and practical companion solutions.
Our mission
To build Better Weight Loss by developing science-led companion products that support health, wellbeing and the changing needs of people on modern weight-loss journeys.
From insight to evidence — fast.
Azento Health was created around the changing needs emerging from modern obesity treatment. We identified the opportunity. We built a defined microbiome platform. We developed Forte80®. We launched the product. We completed a randomized clinical study. We generated real-world patient experience. And we are using those learnings to build a broader pipeline.
01
Insight
02
Product
03
Evidence
04
Platform
That combination of scientific curiosity, commercial focus and execution speed defines how we work.
Big-company experience. Specialist focus. Entrepreneurial speed.
Our leadership team combines experience across obesity and GLP-1 medicines, pharmaceutical commercialisation, microbiome and biotics, nutrition, consumer health, clinical development and entrepreneurship.
Leadership Team
Mads Stoustrup
CEO & Co-Founder
Commercial leader with over 20 years at Novo Nordisk, bringing extensive experience in GLP-1 therapies, obesity treatment, healthcare and business building.
Dr. Peter Kaufmann
CCO, CSO & Co-Founder
Scientist and business leader with over 25 years in pharma and nutrition, a PhD from ETH Zurich and extensive CEO experience.
Jesper N. Gantzel
Chairman & Co-Founder
Entrepreneur with over 20 years of experience building successful businesses, including multiple ventures and exits in probiotics and microbiome science.
Remy Kindle
Sales Director
Commercial and sales specialist with 25+ years’ experience across obesity, diabetes and cardiovascular care, combining knowledge with strong commercial expertise.
Tzvetanka (Tzvety) Nikolova
Business Development Director
Healthcare and nutraceutical leader with extensive experience in sales, commercial development and building businesses across health and nutrition markets.
Scientific Advisors
Professor Stephen Gough
MD, FRCP (UK)
World-leading clinician and pharmaceutical leader in diabetes, obesity and GLP-1–based therapies, with senior leadership experience from Oxford and Novo Nordisk.
“The azh-biotics scientific platform brings an evidence-driven microbiome approach to supporting people on modern Anti-Obesity-Medications along their treatment journeys.”
Scientific expertise that drives innovation.
Azento Health collaborates with experienced scientific and clinical experts across obesity medicine, nutrition, GLP-1 therapies, microbiome science and clinical development.
Their expertise goes beyond advice. They challenge assumptions, strengthen clinical research and help identify unmet patient needs — turning scientific insights into meaningful product innovation.